Welcome to Capten Therapeutics


At Capten, we approach cancer immunotherapy by combining the knowledge gained from cancer vaccine development, specifically haptenated vaccines and immunogenic small molecule natural products. Our proprietary small molecules activate the immune system by enhancing MHC1 and 2 presentation by cancer cells to T cells. Our small molecule drugs are designed using a multipronged approach for achieving desired selectivity and they generate immune response in cells that are highly characteristic of tumor microenvironment, e.g., elevated ROS levels. They may be utilized as single agent drugs or in combination with appropriate existing anticancer drugs.